Semaglutide vs Tirzepatide: The Honest Comparison

Semaglutide and tirzepatide are the two leading weekly GLP-1 medications, and the honest summary is this: tirzepatide produces more average weight loss, both drugs share a gastrointestinal-heavy side-effect profile, and which one is "best" depends on your goals, tolerance, cost, and access rather than a single winner. Semaglutide is sold as Ozempic and Wegovy; tirzepatide as Mounjaro and Zepbound.

This is the head-to-head comparison: mechanism, weight-loss data, side effects, dosing rhythm, cost, and the muscle-loss angle most comparisons skip. It is general education, not medical advice or a dosing protocol, and Myo is not affiliated with any drugmaker.

The core difference: one receptor or two

The mechanistic difference is the whole story. Both drugs are receptor agonists, meaning they switch on a gut-hormone receptor the way the body's own hormone would.

Semaglutide is a single agonist: it activates the GLP-1 (glucagon-like peptide-1) receptor. Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. That second target is widely thought to be why tirzepatide tends to drive larger average weight loss.

Both slow gastric emptying and amplify satiety signaling to the brain, which is why they share most side effects. The extra GIP action of tirzepatide adds to the effect rather than changing the basic category of drug.

Semaglutide vs tirzepatide, side by side

Factor	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist (single)	GLP-1 + GIP receptor agonist (dual)
Brands	Ozempic, Wegovy (Novo Nordisk)	Mounjaro, Zepbound (Eli Lilly)
Average weight loss	~15% at 68 weeks (STEP 1, Wegovy dose)	~16-22.5% by dose at 72 weeks (SURMOUNT-1)
Head-to-head	~13.7% (SURMOUNT-5)	~20.2% (SURMOUNT-5)
Half-life	~7 days	~5 days
Dosing	Weekly subcutaneous injection	Weekly subcutaneous injection
Side effects	GI-predominant (nausea, diarrhea, constipation)	GI-predominant; somewhat higher injection-site reactions
Reported lean-mass loss	Some trials near ~40% of weight lost	Trends lower (~25% of weight lost)

Sources: STEP 1 (NEJM 2021, Wilding et al.); SURMOUNT-1 (NEJM 2022, Jastreboff et al.); SURMOUNT-5 head-to-head data; body-composition substudies (DOM 2025).

Weight loss: what the trials actually found

This is where tirzepatide has the edge, and the data is consistent across both cross-trial and direct comparisons.

For semaglutide, the landmark STEP 1 trial (NEJM 2021, Wilding et al.) followed 1,961 adults with obesity or overweight without type 2 diabetes for 68 weeks. Mean weight loss was about 15.0% on semaglutide 2.4 mg (the Wegovy dose) versus about 2.4% on placebo, and roughly 86% of semaglutide participants lost at least 5% of body weight.

For tirzepatide, SURMOUNT-1 (NEJM 2022, Jastreboff et al.) ran 72 weeks in a similar population. Mean weight loss was about 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus about 2.4% on placebo, with roughly nine in ten participants losing weight.

The cleanest evidence is the head-to-head SURMOUNT-5 trial, which compared the two drugs directly and reported about 20.2% weight loss with tirzepatide versus about 13.7% with semaglutide. So tirzepatide does not just look stronger across separate trials; it won when tested side by side in the same study.

A fair caveat: these are population averages from trial doses, not promises for any individual. Both drugs are highly effective relative to placebo, and "more on average" does not mean "more for you."

Side effects: more alike than different

Both drugs share a side-effect profile dominated by gastrointestinal symptoms, and both follow the same pattern of being worst during dose escalation before easing.

For nausea, semaglutide trials reported a wide range depending on how data was pooled; the Wegovy prescribing information cites up to roughly 44% across all clinical trials, while a pooled three-trial safety set gives about 25% versus 9% on placebo. Tirzepatide in SURMOUNT-1 reported nausea in roughly 25% to 33% of participants depending on dose, versus about 9.5% on placebo. The two are broadly comparable.

Diarrhea and constipation follow similar patterns on both drugs. One area where tirzepatide tends to run higher is injection-site reactions: the SURMOUNT trials reported these more often than the very low rates seen with semaglutide's small-volume injection.

The honest takeaway is that you cannot predict your tolerance from the label. Most side effects are mild to moderate and ease over weeks. Our GLP-1 side effects complete guide covers what is normal, what eases, and what warrants prompt medical attention.

Dosing rhythm and the "dose week"

Both drugs are once-weekly subcutaneous injections, but their pharmacokinetics differ in a way you may feel across the week. Semaglutide has a half-life of about 7 days; tirzepatide's is about 5 days. Half-life is the time it takes for drug levels to fall by half.

That shorter half-life means tirzepatide's blood level drops a bit more steeply toward the end of the dosing week, which some people experience as appetite returning in the day or two before their next dose. Semaglutide's longer half-life tends to produce a flatter, more even level across the week. We explain this pattern in the GLP-1 dose week and PK curve.

Neither drug's actual dose or titration schedule is something we prescribe here; both ramp up gradually under a prescriber's direction, and the specifics belong to your label and your clinician.

Beyond weight: other proven benefits

Weight loss is the headline, but both drugs carry cardiometabolic benefits that matter when comparing them. Semaglutide demonstrated cardiovascular outcome benefits in the SELECT trial, and tirzepatide has its own cardiovascular outcomes program. Both improve blood sugar control, which is why each has a diabetes-indicated brand (Ozempic and Mounjaro).

Tirzepatide also earned an FDA approval that semaglutide does not have: Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, the first GLP-1-class drug cleared for that use. The weight loss itself reduces upper-airway soft tissue and improves sleep apnea severity, and tirzepatide's larger average loss drives a meaningful effect.

So if the comparison were purely "which loses more weight," tirzepatide leads. But if your situation includes a specific condition like sleep apnea or a particular cardiovascular profile, the relevant approved indications can tip the decision in a direction the raw weight-loss percentages do not capture. That is one more reason "better" is situational.

Cost and access

Both are brand-name drugs without generic equivalents, so list prices are high and out-of-pocket cost depends heavily on insurance. Coverage for weight management specifically has been inconsistent for both, though it is improving. Diabetes indications (Ozempic, Mounjaro) are more reliably covered than weight-management indications (Wegovy, Zepbound) under many plans.

Manufacturer savings programs, plan formularies, and the specific brand prescribed all move the real number around, so the practical cost comparison is something to check directly with your pharmacy and insurer rather than assume from list prices.

The muscle angle: bigger loss, bigger stakes

Here is the part most "which is better" comparisons gloss over. Because tirzepatide tends to produce more total weight loss, it can put more absolute lean mass on the line, even though the percentage share of lean mass lost may actually be lower.

Research suggests roughly 25 to 40% of total weight lost on GLP-1 medications can come from lean mass, a category that includes water and organ mass, not only skeletal muscle. The split differs by drug: the SURMOUNT-1 body-composition substudy (DOM 2025) found tirzepatide trending toward the lower end, with fat mass falling about 33.9% and lean mass about 10.9%, while some semaglutide DXA analyses land nearer 40%. In both cases the ratio of fat to lean lost was favorable; participants lost proportionally more fat than muscle.

But "favorable on average" is not automatic. If tirzepatide drops your weight faster and you are not hitting protein or lifting, the larger total loss can mean a larger muscle hit in raw pounds. We break this down in how much muscle you lose on Ozempic and Wegovy and the full picture in the GLP-1 muscle loss complete guide.

The three levers that protect muscle are the same on either drug: adequate protein (a 2025 joint clinical advisory from the Obesity Medicine Association, The Obesity Society, the American Society for Nutrition, and the American College of Lifestyle Medicine recommends about 1.2 to 1.6 g per kg of body weight per day during active weight loss), resistance training at least three times a week, and tracking body composition rather than just the scale.

This is exactly where Myo earns its place in the comparison. The bigger the weight loss a drug delivers, the more your muscle is on the line, and Myo tracks lean mass, protein, and resistance training alongside your dose so you can compare drugs on the metric the trials gloss over: not just how much you lost, but what you lost. Myo is free for tracking one medication, with Premium body-composition analytics at $6.99 per month, $39.99 per year, or $99.99 lifetime. It is a tracking and education tool, not medical advice, and it is not affiliated with Novo Nordisk or Eli Lilly.

So which one is right for you?

There is no universal winner, and anyone who tells you otherwise is selling something. Tirzepatide has the edge on average weight loss, including head-to-head. Semaglutide is highly effective, has a longer track record, and may be better covered or better tolerated for a given person.

The factors that actually decide it are your weight-loss goal, how you tolerate each drug, what your insurance covers, and what is accessible to you. If you are considering moving from one to the other, see switching between semaglutide and tirzepatide, and remember the conversion is a prescriber decision, not a formula.

The bottom line: tirzepatide wins the average-weight-loss matchup, both share a manageable GI side-effect profile, and the larger the loss, the more your protein and training decide whether you keep your muscle. Choose with your clinician, and track the body-composition side no matter which molecule you land on.

References

Semaglutide weight loss (~15% at 68 weeks): STEP 1 (NEJM 2021, Wilding et al., doi:10.1056/NEJMoa2032183).

Tirzepatide weight loss (~16-22.5% by dose): SURMOUNT-1 (NEJM 2022, Jastreboff et al.); Lilly SURMOUNT-1 investor release.

Head-to-head tirzepatide vs semaglutide (~20.2% vs 13.7%): SURMOUNT-5 head-to-head data.

Nausea and GI tolerability: Wegovy prescribing information and Novo Nordisk medlink safety profile; SURMOUNT-1 GI tolerability analysis (DOM 2025, doi:10.1111/dom.16176).

Semaglutide and tirzepatide half-lives (~7 and ~5 days): published pharmacokinetic data.

Lean-mass share of weight lost: SURMOUNT-1 body-composition substudy (DOM 2025, doi:10.1111/dom.16275); STEP 1 and SUSTAIN 8 DXA analyses.

Protein target during weight loss (1.2-1.6 g/kg/day): 2025 joint advisory of the Obesity Medicine Association, The Obesity Society, the American Society for Nutrition, and the American College of Lifestyle Medicine (American Journal of Clinical Nutrition 2025).